Zentalis Pharmaceuticals, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ZNTL Nasdaq 2836 zentalis.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Zentalis Pharmaceuticals, Inc.

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences - Nov 3rd, 2026 2:15 pm
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Nov 2nd, 2026 3:00 pm
Zentalis Pharmaceuticals Announces Meaningful Median Overall Survival Data in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer from DENALI Part 1b to be Presented at the ESMO Congress 2026 - Oct 23rd, 2026 8:15 am
Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 Abstract - Oct 18th, 2026 4:05 pm
Zentalis Pharmaceuticals Shares Rise After Leerink Assumes Coverage With Outperform Rating - Oct 5th, 2026 5:55 am
Zentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares - Aug 17th, 2026 2:01 pm
Sector Update: Healthcare Stocks Decline Late Afternoon - Aug 14th, 2026 1:51 pm
Zentalis Pharmaceuticals Announces Pricing of Underwritten Public Offering - Aug 13th, 2026 8:23 pm
Zentalis Pharmaceuticals Announces Proposed Underwritten Public Offering - Aug 13th, 2026 2:01 pm
Zentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Updates - Aug 6th, 2026 2:05 pm
ZNTL Stock Rises 28% in 3 Months: What's Driving the Rally? - Jul 20th, 2026 7:26 am
Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026 - Jul 17th, 2026 2:15 pm
Zentalis Strengthens Commercial Leadership with Appointments of Shannon Campbell to Board of Directors and Sarah Kelly as SVP of Commercial Strategy - May 27th, 2026 2:05 pm
Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026 - May 21st, 2026 3:39 pm